Transforming growth factor-b (TGF-b) exhibits growth inhibitory effects on various types of tumor cells, including B-cell lymphoma cells. In the present study, the role of TGF-b in the survival of Epstein-Barr virus-negative B-cell lymphoma Ramos cells was investigated. As TGF-b-induced apoptosis of Ramos cells in vitro and in vivo, we attempted to identify novel target gene(s) responsible for their survival. Oligonucleotide microarray analysis and chromatin immunoprecipitation revealed that Smad proteins directly regulated the transcription of membrane-spanning 4-domains, subfamily A, member 1 (MS4A1), also known as CD20, in Ramos cells upon TGF-b stimulation. In addition, immunohistochemical analysis using clinical samples from B-cell lymphoma patients showed an inverse correlation between the expression of MS4A1/CD20 and phosphorylation of Smad3. Although knockdown of MS4A1/CD20 in Ramos cells resulted in an increase of apoptotic cells, Ramos cells stably expressing MS4A1/CD20 were resistant to TGF-b-induced apoptosis. This suggests that MS4A1/CD20 is responsible for TGF-b-induced apoptosis of B-cell lymphoma cells. Moreover, downregulation of MS4A1/CD20 by TGF-b attenuated the effects of the monoclonal anti-MS4A1/CD20 antibody, rituximab, on Ramos cells. Our findings suggest that the sensitivity of B-cell lymphoma cells to rituximab may be affected by TGF-b signaling.
INTRODUCTION
Malignant lymphoma is a group of hematological malignancies, which includes Hodgkin lymphoma and non-Hodgkin lymphoma. Non-Hodgkin lymphoma is generally classified according to origin, that is, B-cell non-Hodgkin lymphoma, which accounts for B80% of all of malignant lymphomas, and T/NK-cell non-Hodgkin lymphoma. 1 Among these subclasses, Burkitt lymphoma, which originates from germinal center B cells, represents highly aggressive non-Hodgkin B-cell lymphoma. Owing to its rapid progression, involvement of the central nervous system, and frequent recurrence after conventional chemotherapy, Burkitt lymphoma is an incurable hematological malignancy. 2 Burkitt lymphoma is divided into the Epstein-Barr virus (EBV)-positive (endemic) subtype and the EBV-negative (sporadic) subtype. 3, 4 Most Burkitt lymphoma cells commonly exhibit translocations between the myelocytomatosis (MYC) oncogene and the immunoglobulin heavy (IGH) chain genes. 5, 6 Transforming growth factor-b (TGF-b) is a prototypic member of a family of secreted proteins that includes three isoforms of TGF-b (TGF-b1, TGF-b2 and TGF-b3), activins and bone morphogenetic proteins (BMPs). TGF-b mediates a wide variety of biological and cellular activities through binding to heteromeric complexes of receptors on the cell surface that are composed of type I and type II receptors. Activin receptor-like kinase (ALK) ALK1 and ALK5 serve as type I receptors for TGF-b, whereas the TGF-b type II receptor (TbRII) acts as the type II receptor for TGF-b. Similarly, ALK1, ALK2, ALK3 and ALK6 function as type I receptors for BMPs, whereas activin type IIA receptor (ActRIIA), ActRIIB and BMP type II receptor serve as type II receptors for BMPs. 7 Upon ligand binding, two type I receptors and two type II receptors form a heteromeric complex, which in turn transduces intracellular signals by phosphorylation of receptor-regulated Smads (R-Smads). Smad2 and Smad3 are TGF-b-specific R-Smads, whereas Smad1, Smad5 and Smad8 are BMP-specific R-Smads. Phosphorylated R-Smads form heteromeric Smad complexes with common-partner Smad, Smad4. Next, the Smad complexes translocate into the nucleus, bind to transcription factors, transcriptional co-activators, and/or corepressors and regulate the transcription of target genes. [7] [8] [9] In addition to the Smad pathway, non-Smad pathways, including various mitogen-activated protein kinase pathways, are activated by TGF-b.
In many epithelial cells, TGF-b inhibits cell cycle progression in the G1 phase through the regulation of p15 INK4B , p21 CIP1/WAF1 and c-Myc. Alterations in TGF-b signaling have been identified in epithelial malignancies. 10, 11 TGF-b also has tumor suppressive activity in some types of hematological malignancies. 12 Loss of Smad3 was observed in T-cell acute lymphoblastic leukemia cells. 13 In acute promyelocytic leukemia blasts, a fusion protein, promyelocytic leukemia-retinoic acid receptor a (PML-RARa), ablates the TGF-b signaling pathway. 14 In malignancies in B cells, several reports have stated that TGF-b inhibits the proliferation of tumor cells in vitro. 15, 16 However, the role of TGF-b signaling during the development of B-cell malignancy is not fully understood.
In the present study, we investigated the role of TGF-b family signaling in the progression of B-cell lymphoma. Human EBVnegative Burkitt lymphoma cells, Ramos, responded to TGF-b and BMP. However, only TGF-b showed suppressive effects on the growth of Ramos cells by inducing apoptosis in vitro and in vivo. Moreover, using oligonucleotide microarray analysis, we identified novel target gene(s) of TGF-b responsible for the survival of Ramos cells under TGF-b signaling.
RESULTS

TGF-b induces apoptotic cell death of Burkitt lymphoma Ramos cells
First, the expression of signal components of TGF-b family signaling in human EBV-negative Burkitt lymphoma Ramos cells was investigated using semiquantitative RT-PCR analysis (Supplementary Figure S1) . Among TGF-b signal components, TGFBR2 (encoding TbRII), TGFBR1 (encoding ALK5), ACTVRL1 (encoding ALK1), SMAD2, SMAD3 and SMAD4 were expressed in Ramos cells. Among BMP signal components, BMPR2 (encoding BMP type II receptor), ACVR2A (encoding ActRIIA), ACVR2B (encoding ActRIIB), BMPR1A (encoding ALK3), BMPR1B (encoding ALK6), SMAD1 and SMAD5 were detected in Ramos cells, whereas ACVR1 (encoding ALK2) and SMAD8 were not present in Ramos cells. We next examined the phosphorylation of R-Smads by TGF-b or BMP in Ramos cells by using immunoblotting (Figure 1a ). Smad2 was phosphorylated by TGF-b3. In addition, phosphorylation of Smad1/5 was enhanced by TGF-b3 as well as by BMP-4 in Ramos cells. We also investigated the upregulation of a TGF-b family target gene, SMAD7, by TGF-b and BMP (Figure 1b) . Quantitative real-time RT-PCR analysis revealed an increase in the expression of SMAD7 mRNA by both TGF-b3 and BMP-4 in Ramos cells. However, the proliferation of Ramos cells was potently inhibited only by TGF-b3, but not by BMP-4 ( Figure 1c ). Cell cycle analysis using flow cytometry revealed that although the ratios of G1, S or G2/M phases were neither affected by TGF-b3 nor by BMP-4, the Sub-G1 population was increased by TGF-b3 ( Figure 1d ). As a Sub-G1 population corresponds to cells undergoing apoptosis, we studied DNA fragmentation by using TdTmediated dUTP-biotin nick end labeling (TUNEL) staining (Figure 1e ). TGF-b3, but not BMP-4, robustly increased the number of TUNEL-positive apoptotic cells. These findings suggest that TGF-b inhibits the growth of Ramos cells by inducing apoptosis.
Next, to investigate the effects of TGF-b signaling on the growth of Ramos cells in vivo, we prepared Ramos cells stably expressing the dominant negative form of TbRII (dnTbRII). Ramos cells were infected with lentiviruses encoding green fluorescent protein (GFP)-tagged dnTbRII, and the GFP-positive sub-population was sorted using flow cytometry (Ramos-dnTbRII cells). Immunoblotting and quantitative real-time RT-PCR analyses revealed that phosphorylation of Smad2 by TGF-b3 and induction of SMAD7 by TGF-b3 were diminished in Ramos-dnTbRII cells compared with control Ramos-GFP cells (Figures 2a and b) . When cells were xenografted into BALB/c nude mice (Figure 2c ), Ramos-dnTbRII cells grew faster than control Ramos-GFP cells. Immunohistochemical analysis of subcutaneous tumors demonstrated that Smad2 phosphorylation was successfully inhibited in tumors from Ramos-dnTbRII cells (Figure 2d ). Furthermore, TUNEL staining revealed that apoptosis in tumors from Ramos-dnTbRII cells was significantly decreased compared with those from Ramos-GFP cells (Figure 2e ). These results suggest that TGF-b inhibits growth of Ramos cells via apoptosis both in vitro and in vivo.
TGF-b negatively regulates the expression of MS4A1/CD20 in Ramos cells To identify target(s) of TGF-b in Ramos cells that contribute to apoptotic cell death, oligonucleotide microarray analysis was performed using Ramos cells stimulated with or without TGF-b3 for 24 h (Figure 3a) . Among 28 869 probe sets, well-known targets of TGF-b, including SMAD7, were increased as expected (Figure 3b ). Translocation between immunoglobulin heavy chain and MYC has an important role in the initiation of Burkitt lymphoma. [3] [4] [5] It is also known that TGF-b inhibits the expression of c-MYC and suppresses cell proliferation. 17 However, in Ramos cells, downregulation of MYC (encoding c-MYC) by TGF-b was not observed in the oligonucleotide microarray analysis (Figure 3b ), and this finding was confirmed using quantitative real-time RT-PCR analysis (Supplementary Figure S2) . Although expression levels of cell cycle regulators were only slightly altered, BCL2L1 (B-cell leukemia/lymphoma 2 (Bcl-2)-like 1, encoding Bcl-X L ) was strongly suppressed (Figure 3b) , and this observation is in agreement with a previous report stating that Bcl-X L prevents Ramos cells from undergoing apoptosis. 18 We also explored other important gene(s) within the category of 'B-cell lymphoma' and identified MS4A1 (membrane-spanning 4-domains, subfamily A, member 1) as a novel target candidate of TGF-b in Ramos cells (Figure 3b ). MS4A1 is also known as CD20, which is an important marker for normal B-cells as well as for various types of B-cell lymphoma cells. [19] [20] [21] As MS4A1/CD20-positive B-cell tumor cells have been identified as targets for treatment using monoclonal antibodies, 21 we focused on the function of MS4A1/CD20 by TGFb in Ramos cells. Expression of MS4A1/CD20 negatively correlates with activation of TGF-b signaling in human B-cell non-Hodgkin lymphoma tissues We investigated whether TGF-b-induced downregulation of MS4A1/CD20 is observed in human B-cell lymphoma tissues. First, MS4A1/CD20 expression in 13 cases of human B-cell non-Hodgkin lymphoma was investigated using immunohistochemical analysis with an anti-MS4A1/CD20 antibody ( Figure 6 ). In eight cases, all lymphoma cells in each slide expressed MS4A1/CD20 as revealed by intense cell surface staining (defined as an MS4A1/CD20-high case). In four other cases, B50% of lymphoma cells within each tumor displayed expression of surface MS4A1/CD20 (defined as an MS4A1/CD20-low case), whereas nearly no expression of MS4A1/ CD20 in any lymphoma cells was observed for one case (defined as an MS4A1/CD20-negative case).
We then evaluated the correlation between expression of MS4A1/CD20 and activation of TGF-b signaling. As accumulation of phosphorylated Smad3 in the nucleus is an indicator of TGF-b signal transduction, serial sections from patients of MS4A1/CD20-high/low/negative cases were stained to determine the phosphorylation of Smad3 ( Figure 6 ). Intense staining for phosphorylated Smad3 was observed in all tumor cell nuclei in the MS4A1/CD20- were sacrificed 17 days after xenograft. Tissue sections were subjected to H-E staining (upper panels). Tissue sections were also subjected to immunostaining using anti-pSmad2 antibodies and counterstained with SYTOX Green Nucleic Acid Stain. Red, pSmad2; Green, SYTOX Green; Scale bar, 50 mm (middle panels, lower panels). Scale bar, 50 mm. (e) Tissues in (d) were also subjected to TUNEL staining. Cell nuclei were counterstained with SYTOX Green Nucleic Acid Stain. Red, TUNEL; Green, SYTOX Green; Scale bar, 50 mm (upper panels). Percentages of TUNEL-positive cells to total cells in three independent fields were counted. Data are presented as the mean ± s.d. (lower panel).
TGF-b-induced apoptosis by MS4A1/CD20 reduction KC Kawabata et al negative case. Although staining for phosphorylated Smad3 in tumor cells was rarely observed in MS4A1/CD20-low cases, negative staining was detected in MS4A1/CD20-high cases. These results suggest that expression of MS4A1/CD20 and activation of TGF-b signaling in human B-cell non-Hodgkin lymphoma tissue are inversely correlated.
TGF-b affects the sensitivity of Ramos cells to rituximab Rituximab is a monoclonal antibody for MS4A1/CD20, which is used for the treatment of MS4A1/CD20-positive mature B-cell lymphoma. Rituximab has antitumor effects through multiple mechanisms, including immunity-mediated cytotoxicity and direct apoptosis induction. 21, 22 Although rituximab is initially effective for many cases of MS4A1/CD20-positive B-cell lymphoma, resistance to rituximab has been frequently observed in the treatment of B-cell lymphoma. 23 As the expression of MS4A1/ CD20 in Ramos cells was downregulated by TGF-b, we hypothesized that the efficacy of MS4A1/CD20-targeting therapy against B-cell lymphoma could be modulated by TGF-b. As documented in previous reports 21, 24, 25 homotypic aggregation observed 48 h after rituximab treatment was used as a marker for sensitivity to rituximab (Figure 7a Mutations in TGFBR2 are observed in many cases of colon cancer. SMAD4 deletions are associated with poor prognosis in pancreatic cancer. 9, 26, 27 Similarly to these malignancies arising in epithelial cells, alterations in TGF-b signal components are also documented in leukemia. Wolfraim et al. 13 reported that loss of Smad3 protein was observed in pediatric T-cell acute lymphocytic leukemia, and that reduction in Smad3 and the loss of p27 KIP1 synergistically promoted leukemogenesis of T-cells in mice. The ecotropic viral integration site-1 (EVI-1) interacts with Smad3 and C-terminal binding protein and acts as a negative regulator of TGF-b signaling. 28 As overexpression of EVI-1 is observed at high frequency in certain types of leukemia patients, high EVI-1 expression is thought to be an independent negative prognostic indicator for some types of leukemia. 29 In B-cell lymphoma, reduced expression of TbRII was reported in EBV-positive B-cell lymphoma cells. In the present study, we attempted to uncover additional mechanism(s) specific to B cells by using microarray analysis (Figure 3a) . Although MYC and other cell-cycle-associated genes were not strongly affected, MS4A1/CD20 was highlighted as a novel direct target of TGF-b in Ramos cells (Figure 3b and Supplementary Figure S2 ). An inverse correlation between MS4A1/ CD20 expression and TGF-b signaling activation was demonstrated in human B-cell non-Hodgkin lymphoma tissues ( Figure 6 ). Moreover, biochemical analysis showed direct binding of the Smad complex to the MS4A1 locus in Ramos cells (Figure 4e ). Sugimoto et al. 32 demonstrated that interferon regulatory factor 4 (IRF4) bound to the MS4A1 promoter in MS4A1-positive B-cell lymphoma cells. We also confirmed that expression of interferon regulatory factor 4 (IRF4) in Ramos cells was downregulated by TGF-b3 (Figure 3b ). These findings proposed another model that TGF-b indirectly regulated the transcription of MS4A1 mRNA through the reduction of IRF4, in addition to the direct regulation of MS4A1/CD20 by TGF-b. interferon regulatory factor 4 might thus be involved in the MS4A1/CD20-mediated cell survival. MS4A1/CD20 is required for the survival of Ramos cells MS4A1/CD20, a member of the MS4A family, is composed of 293 amino acids and forms a 32-kDa protein. Expression of MS4A1/ CD20 is restricted to pre-B cells and memory B cells during differentiation of B cells. MS4A1/CD20 is also expressed in the bone marrow, lymph nodes, thymus, thyroidal glands, the pancreas and the colon. 20, 21, 33 As MS4A1/CD20 forms a homotetramer at the cell surface and acts as a calcium channel, it is thought to act as a receptor for unidentified ligand(s). 
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Previous analyses examining MS4A1/CD20 functions have primarily been conducted using anti-MS4A1/CD20 monoclonal antibodies, including rituximab. Although the precise functions of MS4A1/CD20 in the regulation of cell growth have not been fully investigated, binding of an anti-MS4A1/CD20 antibody to tumor cells inhibited MS4A1/CD20-mediated signal pathways, such as PI3K-Akt, in lymphoma cells. 25, 34 In the present study, we examined the role of MS4A1/CD20 in Ramos cells by using MS4A1/CD20-silenced tumor cells and MS4A1/CD20-overexpressed tumor cells ( Figure 5 ). The knockdown of MS4A1/ CD20 resulted in an increase in apoptosis, whereas stable expression of MS4A1/CD20 in Ramos cells resulted in resistance to TGF-b-induced apoptosis (Figures 5b, e and f) . MS4A1/CD20 is required for the survival of Ramos cells and is responsible for TGFb-induced apoptosis of B-cell lymphoma cells. Moreover, we also attempted to identify the molecular mechanism by which MS4A1/ CD20 exhibited antiapoptotic effect on Ramos cells. Although TGF-b decreased the expression of antiapoptotic factor, Bcl-X L in Ramos cells, forced expression of MS4A1/CD20 did not alter the expression level of Bcl-X L (Figure 3b and Supplementary TGF-b may determine the sensitivity of Burkitt lymphoma cells to rituximab As rituximab has become a first-line treatment for non-Hodgkin lymphomas, our observations provide new insights into the molecular mechanisms governing the treatment of these cancers. Rituximab is a monoclonal anti-MS4A1/CD20 antibody that functions to suppress the growth of MS4A1/CD20-positive B-cell lymphoma cells and MS4A1/CD20-positive leukemia cells. Its antitumor effects are divided into two main mechanisms: immunity-dependent effects, such as complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, and immunity-independent effects. 21, 22 For indolent and aggressive B-cell lymphoma, addition of rituximab to conventional chemotherapy has significantly improved prognosis. 23 However, despite the robust antitumor effects on B-cell lymphoma cells, relapse of the disease with acquired resistance to rituximab is frequently observed. Rituximab-resistant relapse of tumor is explained by many mechanisms. Among these, the activation of PI3K-Akt and the inability to suppress Bcl-X L expression are thought to be involved in the development of rituximab resistance in tumor cells. 34, 35 Moreover, decreased MS4A1/CD20 expression in tumor cells may be another mechanism for this resistance. We hypothesized that TGF-b provided from the tumor microenvironment could downregulate MS4A1/CD20 expression in B-cell lymphoma cells (Figures 4a and b) , leading to a rituximabresistant relapse of B-cell lymphoma. Accordingly, we demonstrated that MS4A1/CD20 expression is inversely associated with the activation of TGF-b signaling in B-cell lymphoma tissues ( Figure 6 ). Moreover, rituximab-induced homotypic aggregation of Ramos cells was not detected upon TGF-b stimulation (Figure 7b) , suggesting an important role of TGF-b signaling in the sensitivity of Burkitt lymphoma cells to rituximab.
In the present study, we investigated the effect of TGF-b and BMP on human Burkitt lymphoma Ramos cells. Disruption of TGF-b signaling in Ramos cells promoted primary tumor growth through apoptosis inhibition in mouse xenograft models. Using oligonucleotide microarray analysis, we identified MS4A1/CD20 as a novel target of TGF-b, which might be responsible for the Figure 6 . Expression of MS4A1/CD20 negatively correlates with activation of TGF-b signaling in human B-cell non-Hodgkin lymphoma tissues. Sections resected from B-cell lymphoma tissues were subjected to H-E staining (left panels), and immunostaining with antibodies specific for MS4A1/CD20 (middle panels) and pSmad3 (right panels). Representative images of sections with high MS4A1/CD20 expression (#1 and #2), sections with low MS4A1/CD20 expression (#3 and #4) and sections without MS4A1/CD20 expression (#5) are indicated. Scale bars indicate 30 mm.
TGF-b-induced apoptosis by MS4A1/CD20 reduction KC Kawabata et al survival of Ramos cells. In addition to previously documented mechanisms, we observed that induction of apoptosis of Ramos cells by TGF-b is mediated by Smad-dependent regulation of MS4A1/CD20. As the anti-MS4A1/CD20 monoclonal antibody rituximab has become the first-line treatment for non-Hodgkin lymphomas, our observations provide new insights into the molecular mechanisms governing the treatment of B-cell lymphoma.
MATERIALS AND METHODS
Cell culture and reagents
Human EBV-negative Burkitt lymphoma Ramos cells were purchased from the American Type Culture Collection and cultured in Roswell Park Memorial Institute (RPMI)-1640 medium containing 10% fetal bovine serum, penicillin (100 units/ml) and streptomycin (100 mg/ml). Cells were grown in a 5% CO 2 atmosphere at 37 1C. Recombinant TGF-b3 and BMP-4 were obtained from R&D Systems (Minneapolis, MN, USA). lY364947, SP600125, SB203580 and LY294002 were obtained from Calbiochem (San Diego, CA, USA). U0126 was obtained from Promega (Fitchburg, WI, USA). Cycloheximide (CHX) was obtained from Sigma (St Louis, MO, USA).
Cell proliferation assay
Ramos cells (1 Â 10 5 cells) were seeded in duplicate in six-well plates. On the next day, cells were treated with TGF-b3 or BMP-4. Cells were counted 72 h after stimulation.
RT-PCR
Semi-quantitative RT-PCR analysis was performed as described. 36 Primers are listed in Supplementary Table S1A . Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used to normalize the total amount of cDNA in each sample. PCR conditions were 35 cycles of 94 1C, (30s), 50 1C (30s) and 72 1C (1 min). Quantitative real-time RT-PCR analysis was performed as described. 36 Primers are listed in Supplementary Table S1B. All samples were run in duplicate for each experiment. Values were normalized to GAPDH levels.
SDS-polyacrylamide gel electrophoresis and immunoblotting
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting were performed as described. 37 The antibodies used are listed in Supplementary Table S1C.
Plasmids and preparation of lentiviral vectors
We used lentiviral vectors to establish Ramos cells stably expressing GFP, dnTbRII, and MS4A1/CD20. 38 Lentiviral vector encoding GFP, CS-CDF-CG-PRE (a gift from Dr Hiroyuki Miyoshi, RIKEN), was used as a control. cDNAs encoding either TbRII that lacks its intracellular domain with a carboxylterminal GFP or MS4A1/CD20 with a carboxyl-terminal FLAG epitope tag were inserted into the lentiviral vector CSII-EF-RfA by using pENTR201, as described. 39 To prepare CSII-EF-MS4A1, full-length MS4A1 was cloned using forward primer 5 0 -GAATTCATGACAACACCCAGAAATTCAGTA-3 0 and reverse primer 5 0 -CTCGAGTTAAGGAGAGCTGTCATTTTCTATT-3 0 .
Oligonucleotide microarray analysis mRNAs were extracted from Ramos cells treated without or with TGF-b3 for 24 h. Total RNAs were used to prepare cDNAs and conduct oligonucleotide microarray analysis using GeneChip Human Gene 1.0 ST Array (Affymetrix, Santa Clara, CA, USA). A heatmap was prepared using Excel software (Microsoft Corp., Redmond, WA, USA).
ChIP
ChIP was performed as described. 40 Whole-cell extracts were incubated at 4 1C for 8 h with Dynabeads sheep anti-mouse IgG (Invitrogen, Carlsbad, CA, USA) that had been preincubated with 10 mg of anti-Smad2/3 antibody (Cell Signaling Technologies, Danvers, MA, USA) in phosphate-buffered saline (PBS) 0.5% bovine serum albumin. Genomic DNA was then extracted using a PCR Purification Kit (Qiagen, Hilden, Germany), eluted in l00 ml of TE, and used for quantitative real-time RT-PCR analysis. Hemoglobin b (HBB) and SMAD7 were used as negative and positive controls, respectively. Primer sequences are listed in Supplementary Table S1D .
Flow cytometry and cell sorting
Ramos cells were labeled with propidium iodide (PI) by using the CycleTEST PLUS DNA Reagent Kit (BD Biosciences, East Rutherford, NJ, USA). The cell cycle distribution of cells was determined using an EPICS-XL flow cytometer (Beckman Colter, Brea, CA, USA) and FlowJo software (Tree Star, Ashland, OR, USA). To analyze the expression of the cell surface MS4A1/CD20 protein, Ramos cells were treated with anti-human MS4A1/ CD20 antibody conjugated with phytoerythrin (PE) or mouse IgG1 antibody conjugated with phytoerythrin for isotype control (BD Biosciences) at a ratio of 40 mg per 1 Â 10 6 cells for 1 h. For cell sorting, an Epics ALTRA cell sorter (Beckman Colter) was used.
RNA interference
Ramos cells were transfected with 20 ml of 100 mM of either Accell siRNA oligoribonucleotides against human MS4A1/CD20 (Thermo Scientific, Figure 7 . TGF-b diminishes sensitivity to rituximab in Ramos cells. (a) Ramos cells were incubated with either human IgG1 (1 ng/ml) or rituximab (1 ng/ml) for the indicated number of hours. Cells were observed by Wright-Giemsa staining. Scale bar, 50 mm. (b) Ramos cells incubated with or without rituximab (1 ng/ml) were simultaneously stimulated with TGF-b3 (1 ng/ml) for 48 h. Cells were subjected to WrightGiemsa staining. Scale bar, 50 mm.
Waltham, MA, USA) or control siRNA by using 80 ml Accell siRNA delivery media (Thermo Scientific) in a six-well plate.
Rituximab-mediated cell aggregation
To examine the effect of rituximab (Chugai, Tokyo, Japan) on Ramos cells in vitro, we observed homotypic cell aggregation, as reported. 24, 41 Ramos cells (1 Â 10 5 cells) were seeded on a six-well plate, and rituximab (137 nM) was added in the presence or absence of TGF-b3 (1 ng/ml). Human IgG1 (Sigma) at the same concentration was used as a negative control. Cells were cultured for indicated hours and then centrifuged with Cytospin2 (Shandon, Pittsburgh, PA, USA) to prepare smears on glass slides. Samples were stained with Wright's stain solution (Nacalai Tesque, Kyoto, Japan) and Giemsa's stain solution (Muto Chemical, Tokyo, Japan) and observed using BZ-9000 (Keyence, Osaka, Japan).
Subcutaneous xenograft transplantation of Ramos cells to BALB/c nu/nu mice BALB/c nu/nu male mice (4 weeks of age) were obtained from Oriental Yeast Co. (Tokyo, Japan). All animal experiments were performed in accordance with the policies of the Animal Ethics Committee of the University of Tokyo. A total of 1 Â 10 7 cells per 100 ml of culture medium were injected into the left flank of each mouse. Tumor volume was approximated as described. 38 To investigate the effects of rituximab on subcutaneous tumor growth, rituximab (200 mg/mouse) was administered into the right flank 3 days and 7 days after injection of Ramos cells. 42, 43 TUNEL staining Cells were centrifuged with Cytospin2 and fixed in 3.7% formaldehyde. After permeabilization in diluted H 2 O containing 0.1% Triton X-100, the In situ Cell Death Detection Kit (TMR red; Roche Diagnostics, Basel, Switzerland) was used as described. 36 Fluorescence was examined using BZ-9000. Percentages of TUNEL-positive cells to total cells in independent fields were counted. For excised mouse tissue samples, frozen samples were further sectioned at a thickness of 8 mm, briefly fixed in 3.7% formaldehyde, and then treated with proteinase K (5 mg/ml; Stratagene, La Jolla, CA, USA). After permeabilization in 0.1% Triton X-100, TUNEL staining was performed using the same procedure.
Immunostaining of mouse tissues
Excised mouse tissue samples were fixed for 1 h in 10% neutral-buffered formalin at room temperature, washed overnight in phosphate-buffered saline containing 10% sucrose at 4 1C and embedded in Tissue-Tek optimal cutting temperature compound (Sakura Finetek, Torrance, CA, USA). Some samples were frozen immediately in a dry ice-acetone bath for TUNEL staining and other samples were fixed overnight in 4% paraformaldehyde and then embedded in paraffin for immunostaining. Formalin-fixed samples of subcutaneous tumors were subjected to immunostaining or hematoxylin and eosin (H-E) staining. Anti-phosphorylated Smad2 antibody (pSmad2, Ser465/467; Millipore, Billerica, MA, USA) was used.
Immunostaining of human B-cell lymphoma tissues B-cell lymphoma tissues were obtained from patients with B-cell nonHodgkin lymphoma at The Cancer Institute Hospital of Japanese Foundation for Cancer Research (JFCR) under a blanket written informed consent. Tissue sections were prepared from paraffin blocks. Sections were incubated with antigen retrieval solution (10 mM sodium citrate, pH 6.0) at 105 1C for 10 min. Sections were immunostained with a primary antibody for phosphorylated Smad3 (pSmad3, Ser423/425; Rockland, Gilbertsville, PA, USA) or a primary antibody for MS4A1/CD20 (Dako, Kyoto, Japan). Stained sections were treated using biotinylated secondary anti-rabbit IgG and visualized using the Vectastain ABC Kit (Vector Laboratories, Burlingame, CA, USA). For control experiments, primary antibody was omitted.
